Results 101 to 110 of about 4,166,301 (304)

Inebilizumab in AQP4‐Seropositive NMOSD: One‐Year Follow‐Up From a Multicenter, Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Real‐world evidence on inebilizumab among neuromyelitis optica spectrum disorder (NMOSD) patients is lacking. This study assessed inebilizumab among Chinese patients with aquaporin 4 autoantibody (AQP4‐IgG)‐seropositive NMOSD in a real‐world setting.
Mengcui Gui, Jiayang Zhan, Wei Li, Tao Jin, Dan He, Daishi Tian, Zhijun Li, Jing Lin, Yue Li, Hongyu Zhou, Bitao Bu   +10 more
wiley   +1 more source

Adverse drug reactions [PDF]

British Journal of Clinical Pharmacology, 2015
Michael, Rieder, Albert, Ferro
openaire   +2 more sources

A structural equation model of adverse events and length of stay in hospitals [PDF]

Adverse events in hospitals cause significant morbidity and mortality, and considerable effort has been invested into analysing their incidence and preventability. An unresolved issue in models of medical adverse events is potential endogeneity of length
Katharina Hauck, Xueyan Zhao
core  

Ofatumumab Therapy and Long‐Term Seizure Outcomes of Patients With Relapsing Anti‐NMDA Receptor Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There is a lack of studies on seizure outcomes associated with ofatumumab therapy in patients for relapsing anti‐N‐methyl‐D‐aspartate (NMDA) receptor encephalitis. We aimed to evaluate long‐term seizure outcomes of ofatumumab therapy for relapsing anti‐NMDA receptor encephalitis.
Jian Wang, Mengjiao Li, Ping Kong
wiley   +1 more source

http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-76102 Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions –

, 2014
Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions- a meta ...
Katja M Hakkarainen, Khadidja Hedna, Percentage Of, Staffan Hägg, Katja M. Hakkarainen, Max Petzold, A Meta-analysis   +6 more
core  

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Adverse drug reactions and drug interactions

, 2017
This chapter provides an overview of adverse drug reactions and drug interactions for pharmacists and other healthcare professionals. It provides a practical guide to determining whether a reaction is related to the drug or disease.
Marc Mitchell, Nicola Stoner, Melanie Snelling, Philip Wiffen   +3 more
core   +1 more source

Artificial Intelligence–Based Online Symptom Assessment Tools for Systemic Lupus Erythematosus Diagnosis: Patient Perspectives

Arthritis Care &Research, EarlyView.
Objective The objective of this article is to identify perceptions of patients with systemic lupus erythematosus (SLE) regarding artificial intelligence (AI)–based online symptom assessment tools, and the potential of these tools to address diagnostic barriers.
Olivia A. Stein, Jennifer L. F. Lee, Evelyne Vinet, Arielle Mendel, Christian A. Pineau, Fares Kalache, Louis‐Pierre Grenier, Sasha Bernatsky   +7 more
wiley   +1 more source

Precision dosing to avoid adverse drug reactions

Therapeutic Advances in Drug Safety, 2019
Adverse drug reactions (ADRs) have traditionally been managed by trial and error, adjusting drug and dose selection reactively following patient harm. With an improved understanding of ADRs, and the patient characteristics that increase susceptibility ...
Thomas M. Polasek, Carl M. J. Kirkpatrick, Amin Rostami-Hodjegan   +2 more
doaj   +1 more source

Pharmacogenetics and adverse drug reactions

, 2010
The rapidly expanding discipline of pharmacogenetics has helped to explain the mechanisms of susceptibility to several adverse drug reactions. The molecular details of the 'classical' adverse reactions, including malignant hyperthermia, haemolysis in ...
Robin E Ferner, Jeffrey K Aronson
core   +1 more source